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GLOSSARY 
 
AGEs: Advanced Glycation End products 
CML: N(epsilon)-Carboxymethyllysine 
ELISA: Enzyme-Linked Immunosorbent-Assay 
esRAGE: endogenous secreted RAGE 
HCC: Hepatocellular Carcinoma 
HMGB-1: High-Mobility Group Box 1 
HSCs: hepatic stellate cells 
LECs: liver sinusoidal endothelial cells 
LT: Liver Transplantation 
MELD: Model of End-Stage Liver Disease 
NAFLD :Non-Alcoholic Fatty Liver Disease 
NASH: Non-Alcoholic Steatohepatitis 
RAGE: Receptor for AGEs 
ROS: reactive oxygen species 
RT-PCR: Reverse Transcriptase-Polymerase Chain Reaction 
sRAGE: soluble RAGE 
TNF-α: tumor necrosis factor-α 
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ABSTRACT 
BACKGROUND. In animal testing the blockade of the receptor for advanced glycation 
end products (RAGE) attenuates the liver injury extent induced by RAGE-ligands. 
Likewise circulating truncated soluble isoforms of RAGE (sRAGE), acting as decoy of 
RAGE-ligands, protects by injury. 
AIM. The primary objective of this study was to investigate the association between 
tissue RAGE isoform (both full-length and truncated) mRNA expression with both 
recipient liver disease and early outcomes after liver transplantation. Secondarily, to 
evaluate trends of circulating RAGE-ligands and of protective sRAGE in the immediate 
period following transplantation and their association with the development of early 
organ dysfunction 
METHODS. We prospectively included 28 adult LT recipients (53±8.7 years) of 
primary whole-size grafts by deceased donors (62.1±17.3 years). In liver biopsies of 
both donor and LT recipients, we measured the transcriptional expression of full-length 
RAGE and its truncated isoform, the endogenous secreted RAGE (esRAGE). The 
RAGE-ligands — N(epsilon)-carboxymethyllysine (CML) and high-mobility group 
protein 1 (HMGB-1) — and the circulating sRAGE were measured in plasma 
specimens before LT, after graft reperfusion, 1 and 7 days after LT. 
RESULTS. In LT recipients the hepatic RAGE mRNA levels were higher than in 
healthy donors (p<0.01). In LT recipients the tissue full-length RAGE inversely 
correlated with antithrombin III (β= -0.58, p = 0.013) and cholinesterase plasma levels 
(β= -0.717, p= 0.0018) and directly correlated with MELD score before LT, likewise to 
basal HMGB-1 plasma levels (β=0.425, p=0.043 and β=0.448, p<0.05 respectively). 
Basal CML levels were higher in LT recipient than donors (p=0.02), decreased after 
graft reperfusion (p<0.0001) but returned progressively to basal values at 7 days after 
LT. HMGB-1 levels increased after graft reperfusion (p<0.0001) and returned suddenly 
to basal values one day after LT while circulating sRAGE did not change soon after LT 
but decreased significantly 7 days after LT (p<0.0001). The MELD score 7 days after 
LT inversely correlated with graft esRAGE mRNA expression (β= -0.487, p=0.029) and 
tended to correlate directly with the peak values of HMGB-1 after reperfusion (β = 0.42, 
p = 0.07), with recipient age (β = 0.38, p = 0.07) and recipient gender (β = 0.49, p = 
0.015). Multivariate analysis showed that, after adjustment for gender, donor age, 
recipient age, only graft esRAGE mRNA expression was a significant determinant of 
MELD score 7 days after LT (β= -0.788, p=0.0005). 
CONCLUSIONS. The inverse correlation between graft esRAGE mRNA expression 
and the MELD score 7 days after LT underline the importance of this protective factor 
for graft survival and patient outcomes. CML accumulation and rapid increase of 
HMGB-1 followed by remarkable decline of protective sRAGE could have deleterious 
consequences on graft survival and long term outcomes in LT recipients. 
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Liver structure, cell types and functions 
The liver is the largest gland in the body, consists of two lobes which are wedge-shaped 
and is situated slightly below the diaphragm and anterior to the stomach. Each lobe is 
further divided into many small lobules, each being about the size of a pin-head, and 
consisting of many liver cells, with bile channels and blood channels between them. 
Two blood vessels enter the liver, namely the hepatic portal vein with dissolved food 
substances from the small intestine, and the hepatic artery, with oxygenated blood from 
the lungs. Sinusoids are low pressure vascular channels that receive blood from terminal 
branches of the hepatic artery and portal vein at the periphery of lobules and deliver it 
into central veins [1]. 
The liver, as metabolic center of the body, performs several important functions 
including control of carbohydrate and lipid metabolism, bile production, red blood cell 
decomposition, plasma protein synthesis, hormone production, detoxification by 
harmful substances (e.g. alcohol, drugs and also advanced glycation endproducts, 
AGEs) [2, 3]. The liver is unique in its ability to undergo compensatory hyperplasia 
after cell loss by restoring key tissue loss within a few weeks through a complex 
network of cells and mediators [4]. 
The liver is composed by different cell types, the parenchymal cells, i.e. hepatocytes, 
perform the majority of functions including the bile production, while the 
nonparenchymal cells, represented by three cell types: liver sinusoidal endothelial 
cells (LECs), Kupffer cells, and hepatic stellate cells (HSCs) that play different roles 
(Fig. 1). LECs form the wall of sinusoids and perform important filtration function due 
to the presence of small fenestrations that allow free diffusion of many substances 
between the blood and the hepatocyte surface [5]. Kupffer cells are the liver-resident 
macrophages intrasinusoidally located that modulate the immune function of the liver 
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and secrete potent mediators of the early inflammatory response like reactive oxygen 
species (ROS), tumor necrosis factor-α (TNF-α) and other cytokines. Besides typical 
macrophage activities, Kupffer cells play an important role in the clearance of senescent 
and damaged erythrocytes [5]. HSCs, located in the perisinusoidal space, store vitamin 
A, control the turnover of extracellular matrix, and regulate the contractility of sinusoids 
modulating sinusoidal flow [5]. Acute damage to hepatocytes activates transformation 
of quiescent HSCs into myofibroblast-like cells that play a key role in the development 
of inflammatory fibrotic response (see below). 
 
 
 
Fig. 1. Cell types organization in liver lobule 
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Liver transplantation and graft dysfunction 
Liver transplantation (LT) represents the lifesaving procedure for patients with chronic 
end-stage liver disease and acute liver failure (ALF) when there are no alternative 
treatment options. Incurable chronic liver diseases include liver-based metabolic defect, 
unresectable hepatocellular carcinoma (HCC), or more commonly, cirrhosis with 
complications such as hepatic encephalopathy, ascites, hepatorenal syndrome, or 
bleeding caused by portal hypertension [6, 7]. 
After allocation to candidates with fulminant hepatic failure, which is fatal within days, 
the waiting list is sequenced by decreasing model for end-stage liver disease (MELD) 
score, a very strong predictor of waiting list mortality, that frequently change over time 
[7]. A recent retrospective survey underscored, among several studied indexes, that the 
APACHE II death risk scoring system and the MELD score post-LT, may indicate 
which patients are at higher risk of early mortality (up to 30 post-transplantation 
days) [8]. 
After liver transplantation, about 25% of recipients develop early allograft dysfunction 
(EAD), a condition that is associated with significantly decreased graft and patient 
survival [9]. The concept of early graft dysfunction is not yet clear. There is a spectrum 
of “graft dysfunction” events: primary nonfunction (PNF), delayed nonfunction, initial 
poor function (IPF), initial nonfunction, primary graft failure, and primary dysfunction. 
A distinction among these entities considers the grade of dysfunction, the need for 
urgent retransplantation, and their timing and length after LT [10]. According to the 
United Network for Organ Sharing (UNOS), primary dysfunction is defined as 
unrecoverable graft function needing urgent liver replacement during the first 10 days 
after LT. It is characterized by an aspartate amino transferase (AST) ≥ 5000 UI/L, an 
international normalized ratio of prothrombin (INR) ≥ 3.0, and acidosis (pH ≤ 7.3 
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and/or lactate concentration ≥ 2× normal) [10]. The factors that may impact the 
occurrence of EAD could be: donor-related factors, including advanced donor age and 
steatotic graft, and recipient-related factors, including higher MELD scores, septic 
complications, rejection and biliary complications, among which the age of the donor 
and MELD score represented the best predictive factors for EAD onset [9, 11]. 
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Cellular mechanisms of graft dysfunction: ischemia/reperfusion (I/R) injury 
Ischemia/reperfusion (I/R) injury results from a prolonged ischemic insult followed by 
restoration of blood perfusion, and it is a pivotal phase in transplantation, and in 
particular in LT, in which the damage is sustained during cold preservation of the liver 
following explantation from the donor, and during subsequent warm reperfusion at 
implantation into the recipient [12]. The development of EAD is often thought to be 
secondary to substantial I/R injury, which is associated with acute cellular damage, cell 
death, oxidative damage from the creation of ROS, and a severe inflammatory response 
occurring within the liver [9, 13]. The degree of I/R injury sustained is dependent on the 
length and method of ischemia applied to the liver, as well as the background liver 
condition. Moreover, patients who undergo short periods of ischemia sustain less liver 
dysfunction compared to those undergoing a long period of ischemia [14]. 
Liver I/R injury is a complex process involving numerous cell types among which 
Kupffer cells play a key role in initiating and propagating cellular damage and death in 
I/R injury, they are activated during the ischemic phase and even more so on 
reperfusion [12]. During the ischemic phase, as a result of glycogen consumption and 
lack of oxygen supply, Kupffer cells, SECs, and hepatocytes suffer with lack of 
adenosine triphosphate (ATP) production. This lack leads to dysfunction in homeostatic 
processes that carry out edema and swelling. Kupffer cells and LECs swelling, 
combined with an increase in the vasoconstrictors endothelin and thromboxane A2 due 
to the reoxygenation, and a decrease in the vasodilator nitric oxide, lead to activation of 
HSCs and constricting hepatic sinusoids. The end result is the significant reduction of 
microcirculatory blood flow on reperfusion, including some areas with complete 
absence of blood flow, which is known as “no-reflow” [15]. 
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One of the principal actors involved in the I/R dangerous processes, and that is released 
in response to hypoxia, is the nuclear transcription factor high mobility group box-1 
(HMGB-1). HMGB-1 is a DNA-binding protein present in the nucleus of almost all 
eukaryotic cells which can be either released passively by necrotic hepatocytes or the 
damaged extracellular matrix, or is actively secreted, following cytokine stimulation, by 
stressed and injured liver cells, so its levels are significantly elevated in the serum and 
liver tissue after I/R, and it can lead to prolonged liver injury [16]. HMGB-1 exert its 
effects by binding to a group of receptors among which there are the toll-like receptors 
(TLRs), that include the receptor for advanced glycation end products (RAGE) (Fig. 
2). 
HMGB-1 and other mediators released by necrotic hepatic cells represent the 
inflammatory signal transduction mediators that cause activation of hepatocytes and 
Kupffer cells leading to the activation of the nuclear factor kappa B (NF-κB) pathway 
[17]. This activation leads to the expression of many cytokines and chemokines, 
including TNF-α, interleukin-1b (IL-1b), IL-6 and IL-8 that in turn induce expression of 
many other inflammatory mediators in injured liver tissue [18, 19]. TNF-α is the central 
component of the proinflammatory cytokine cascade in liver I/R injury and acts both 
locally in a paracrine fashion, and remotely as an endocrine mediator. The up-regulation 
of TNF-α leads to liver damage by binding to specific receptors on the surface of 
hepatocytes and this results in increased production of ROS, and further activation of 
NF-κB [19]. 
ROS have widespread effects in the initiation and propagation of I/R injury. During 
oxidative stress, localized expression of monocyte chemotactic protein-1 (MCP-1) 
attracts monocytes and activated lymphocytes to sites of injury. Likewise, IL-8 causes 
sinusoidal neutrophil sequestration and resultant hepatocellular damage [18, 19]. 
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Moreover ROS can activate SECs, leading them to NF-κB mediated expression of cell-
surface adhesion molecules (i.e. intercellular adhesion molecule-1, ICAM-1 and 
vascular adhesion molecule-1, VCAM-1), that lead to further monocytes adhesion to I/R 
injured site [20]. Therefore, excessive activation of the NF-κB pathway may be 
detrimental to early liver allograft function post-transplantation. A link between NF-κB 
regulation and EAD was anticipated because induction of the NF-κB-associated genes 
in Kupffer cells is an early event following I/R injury, and serves as a point of 
convergence for molecular signals inherent in many forms of chronic liver disease. 
Actually, EAD is associated with early post-operative increases in MCP-1, IL-8, and IL-
6 whose expression is driven by NF-κB activation [21]. 
 
 
 
Fig. 2. The RAGE-HMGB-1 interaction mediated signal transduction pathway in liver cells 
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RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (RAGE) 
 
Structure of RAGE and soluble forms of RAGE: the cleaved-form and splicing 
variant esRAGE 
The RAGE is a multiligand-binding member of the immunoglobulin superfamily of cell-
surface molecules [22]. The full length receptor consists of an extracellular region 
formed by one V-type immunoglobulin domain, needed for ligand binding, and two C-
type immunoglobulin domains, followed by a single, short transmembrane domain and a 
short cytoplasmic domain, that is essential for RAGE-mediated signal transduction [22, 
23] (Fig. 3). RAGE is expressed on many cells including endothelial cells, mononuclear 
phagocytes, lymphocytes, vascular smooth muscle cells, neurons and some cell types of 
the liver [6, 22, 24]. The RAGE is typically expressed at low levels under normal 
physiological conditions in the majority of tissues and organs, except in the lung where 
exhibits high basal levels of expression. High levels of RAGE expression occur in the 
other tissues only under pathological conditions [25-28]. The biological activity of 
RAGE is dependent on its ligation by various ligands, released by inflamed, stressed and 
damaged cells [29]. 
Its name is derived from the first-known ligands, the advanced glycation endproducts 
(AGEs), a complex and heterogeneous group of tissue-bound and circulating 
glycoxidated proteins, of which the carboxymethyl-lysine adducts (CML) are the 
most abundant [30]. Apart the AGEs, that are occasional ligands, the RAGE binds the 
non-histone nuclear factor high-mobility group box 1 protein (HMGB-1), certain 
members of the S100/calgranulin proinflammatory cytokine family, the β-amyloid 
peptide, the β-sheet fibrils and others [31-34]. Increased expression of both cell-surface 
RAGE and accumulation of its ligands are observed in a range of disorders 
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characterized by chronic inflammation, such as inflammatory bowel disease, 
rheumatoid arthritis, atherosclerosis, amyloidoses, tumors, Alzheimer’s disease, the 
vascular complications of diabetes and in liver impairment [35, 36]. 
Besides the full-length receptor, several truncated isoforms of the RAGE have been 
described, some of which are soluble isoforms containing only the extracellular portion 
of the full-length receptor and that are detectable in circulating blood (reviewed in Ref. 
[37]). Two major RAGE mRNA splice variants have been thoroughly characterized. 
One variant protein (N-truncated type) lacks the V-type immunoglobulin domain, but it 
is otherwise identical to full-length RAGE and is retained in the plasma membrane [38] 
(Fig. 3). As a result of the deletion of the V-type immunoglobulin domain, this variant 
protein is significantly impaired in its ability to bind RAGE ligands [38]. The other 
variant (C-truncated type), named endogenous secreted isoform (esRAGE), 
containing the same immunoglobulin domains present in full-length RAGE, but lacking 
the cytosolic and transmembrane domains [38], is secreted extracellularly and can be 
detected in circulating blood. 
Total circulating isoforms of RAGE, overall named soluble RAGE (sRAGE), include 
both esRAGE and a truncated form generated through proteolytic cleavage of the full-
length cell-surface receptor, probably mediated by membrane metallopeptidases, 
including ADAM10 [39] (Fig. 3). Both esRAGE and the cleaved-type of soluble RAGE 
are still able to bind ligands and, by competing with membrane-bound RAGE for ligand 
binding [38, 40], can have cytoprotective effects [38, 41]. Higher circulating levels of 
sRAGE are associated with reduced risk of coronary artery disease (CAD), 
hypertension, metabolic syndrome, and other chronic diseases [42-45]. 
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Fig. 3. The structure of RAGE and its soluble forms. 
 
 
16
Expression of RAGE and esRAGE in liver tissue 
In literature, conflicting evidences about the RAGE expression and localization among 
the different cell types of the liver and across different species, have been reported. The 
first evidence of the expression of this receptor in normal liver tissue, dates back to 
1993 when in bovine liver the RAGE was found in hepatocytes, whereas no significant 
expression was detected in Kupffer cells and LECs [25]. More recently, Butscheid et al. 
[46] reported marked levels of RAGE in hepatocytes and in bile ducts of healthy human 
liver and a weak staining for RAGE in Kupffer cells. 
Conversely, another study later revealed that RAGE was exclusively expressed by 
HSCs isolated from rat liver [47], whereas no transcripts were seen in hepatocytes, 
Kupffer cells, or LECs isolated in both rat and mouse liver [3, 47]. Another study 
performed on human HSC lines highlighted the expression of RAGE at both transcript 
and protein levels [48]. These results have been confirmed in rat and human HSC lines 
that expressed significant RAGE while no RAGE expression was found in rat 
hepatocytes [49]. The discrepancies among RAGE expression patterns described by 
different research groups may be due to dissimilar experimental settings that included 
the use of antibodies with different specificities. 
However, summarizing these studies it may be essentially said that there is a cell 
specific pattern of RAGE expression and there is enough agreement that the RAGE is 
poorly or not expressed in Kupffer cells and LECs in almost all species analyzed, while 
it is markedly expressed in HSCs and in hepatocytes [6]. 
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INVOLVEMENT OF RAGE-LIGAND AXIS IN LIVER DISEASES 
 
The catabolism of AGEs: lack of RAGE involvement 
RAGE is associated with many inflammation-related pathological states [36, 50], but 
there is no evidence that it plays a catabolic function. On the other hand, in the liver 
such a function is carried out by other AGE-receptors that act mainly as scavenger 
receptors for AGE detoxification and catabolism [3, 46, 51]. This has been shown in an 
in vivo study in rats demonstrating that the liver removed from the circulation more 
than 90% of intravenously injected AGEs via endocytosis mediated by scavenger 
receptors in LECs (60%) and in Kupffer cells (25%), whereas the contribution of 
hepatocytes was low (10-15%) [52 ]. These results were later confirmed in cultured 
LECs incubated with AGEs and whose intracellular uptake was mediated by scavenger 
receptors [52 ]. Furthermore, experiments utilizing peritoneal macrophages and LECs 
derived from macrophage class-A scavenger receptors (MSR-A) knock-out mice, 
showed that in peritoneal macrophages AGEs were endocytosed almost exclusively 
through MSR-A, whereas in LECs the uptake of AGEs took place through a pathway 
distinct from MSR-A [3, 53]. Another study performed on biopsy specimens from 
patients with varying degrees of hepatic dysfunction revealed that, irrespective of 
diagnosis, CML and galectin-3 (another AGE-scavenger receptor), but not RAGE, were 
highly expressed in Kupffer cells [46]. Therefore, AGE catabolism does not seem to be 
mediated by RAGE for three reasons: first, expression of RAGE in hepatic cells 
involved in AGE-endocytosis (mainly LECs and Kupffer cells) is null or weak; second, 
RAGE is functionally similar to a cell signaling receptor rather than a scavenger 
receptor, and thirdly scavenger receptors (i.e., galectin 3 and MSR-A) for AGEs also 
exist in the liver [3, 46]. Since the liver is the major site of AGE catabolism, whatever 
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the scavenger receptors involved in endocytosis of AGEs may be, a consequence of 
impaired hepatic function is the increase of circulating AGEs levels, which can exert 
their detrimental effects on the whole organism. 
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Pre-clinical studies: RAGE involvement in liver fibrosis 
The first study on the role of RAGE in hepatic injury, was carried out in a mouse model 
of total hepatic ischemia/reperfusion (I/R) in which the blockade of the RAGE, through 
administration of sRAGE, which functions as a ligand-competitor, protected against the 
hepatocellular necrosis, attenuated liver I/R injury and enhanced the expression of the 
proregenerative cytokine TNF-α [54]. Recently, in the same model, it has been shown 
that early growth response-1 (Egr-1), an inducible transcription factor activated by 
stress stimuli, was upregulated in the liver remnants after hepatic I/R injury and it was 
suppressed by administration of sRAGE or in RAGE knock-out mice [55]. Moreover, 
the RAGE-ligand HMGB-1, released from necrotic cells or following induced hypoxia, 
was upregulated after I/R in the liver remnants and it can limit liver regeneration and 
response to I/R injury [16, 55]. 
So, the activation of RAGE may contribute to induction of pro-inflammatory and tissue-
destructive processes on hepatic I/R, and the blockade of RAGE may limit immediate 
deleterious inflammatory mechanisms, and thereby facilitate regenerative potential in 
the injured liver offering a potential target in clinical transplantation. 
In a mouse model of hepatectomy, RAGE was up-regulated in liver remnants after 
massive versus partial hepatectomy, principally in monocyte-derived dendritic cells 
[56]. Blockade of RAGE, using pharmacological antagonists or transgenic mice in 
which a signaling-deficient RAGE mutant is expressed in cells of monocyte lineage, 
significantly increased survival of the mice after massive liver resection and increased 
proliferation and reduced apoptosis of hepatocytes in liver remnants [56]. Furthermore, 
liver remnants retrieved from RAGE-blocked mice displayed enhanced expression of 
TNF-α and IL-6, cytokines promoting inflammation and regeneration and of the anti-
inflammatory IL-10, suggesting that the RAGE mediates injurious stress responses in 
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liver resection and initiates events that critically curtail the limits of regeneration while 
the RAGE blockade may be a novel strategy to promote regeneration in the massively 
injured liver [56]. 
The active involvement of RAGE in the liver was shown also in an acetaminophen-
induced hepatotoxicity in a mouse model in which the treatment with sRAGE increased 
the animal survival, attenuated the hepatotoxicity, decreased the hepatic necrosis and 
enhanced the expression of TNF-α and IL-6 [57]. 
Excluding the lung in which physiological high levels of RAGE expression seem to 
have a protective role in preventing pulmonary fibrotic disease, high expression levels 
of RAGE seem be instead associated to renal and liver fibrosis [49, 58, 59]. 
A number of studies have reported that the RAGE expression is up-regulated during the 
trans-differentiation of HSCs to myofibroblasts, their spreading and migration [47, 60, 
61].  
As previously described, after hepatic I/R injury, there is an inflammatory milieu and 
HMGB-1 is actively and passively released by the damage liver cells [62] and, through 
RAGE engagement, it can directly activate HSCs and drives them toward fibrogenesis, 
stimulating cell proliferation and alpha-smooth muscle cells (α-SMA) gene and protein 
expression and suppressing MMP-2 activity (Fig 4). This process seems not to be 
mediated by CML or AGEs [49]. In addition, in rats in which liver fibrosis was induced 
by bile duct ligation or through thioacetamide treatment, the RAGE expression and the 
α-SMA transcript, were up-regulated in the cirrhotic liver [49]. 
Recently, in the same animal model, AGEs administration significantly increased 
collagen content and α-SMA expression, that are markers of hepatic fibrosis, compared 
with bile duct ligation alone. Moreover, AGEs increased hepatic oxidative stress and 
RAGE gene expression, suggesting that AGEs may contribute to the pathogenesis of 
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chronic liver injury and fibrosis [63]. In another rat model in which hepatic fibrosis at 
different stages was induced by carbon tetrachloride, the gene silencing of RAGE 
suppressed NF-κB activity, HSCs activation, and accumulation of extracellular matrix 
proteins in the fibrotic liver, improving the ultra-structure of liver cells [59]. Altogether 
these observations suggest that the RAGE may be implicated in the initial processes of 
liver fibrosis and that the RAGE-blockade or the RAGE-gene silencing may be a 
therapeutic modality to prevent fibrogenesis in post-transplant liver grafts. 
 
 
 
Fig. 4. The role of RAGE in hepatic fibrosis 
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Clinical association studies 
The liver being a multifunctional organ (specialized in detoxification, metabolism and 
defence), is also prone to many diseases including non-alcoholic fatty liver disease 
(NAFLD), non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and hepatocellular 
carcinoma (HCC). Histologically indistinguishable from alcoholic liver disease, the 
exact etiology of NAFLD remains unknown, but the fundamental pathophysiological 
process appears to be insulin resistance and oxidative stress related to the metabolic 
syndrome [64], and NASH is the more severe form of NAFLD. 
Several clinical studies have suggested the involvement of ligands (AGEs, CML, 
HMGB-1) and RAGE (tissue-bound and soluble form) in different liver diseases such as 
NASH, liver cirrhosis and HCC. 
Butscheid et al. [65] have not found any difference in CML levels among patients with 
hepatitis C virus (with or without fatty liver), with NAFLD or with NASH. Conversely, 
in patients with liver cirrhosis, high levels of circulating CML correlated positively with 
the severity of the disease and inversely with residual liver function [66]. Further, serum 
CML levels that were significantly higher in patients with chronic liver diseases than 
healthy controls, were found closely associated with liver function capacity [67]. 
Although apparently discordant, taken together these results suggest that a moderate 
impairment in hepatic function does not affect circulating CML levels that instead 
increase in severe cirrhosis as consequence of a reduced AGE-catabolism rather than as 
cause of the disorder. 
In a recent study serum levels of HMGB-1 were found significantly higher in patients 
with chronic hepatitis B virus and with low fibrosis compared to controls [68]. 
The levels of circulating sRAGE, the cell-membrane RAGE competitor for ligand 
binding, were found significantly lower in patients with NASH but not in patients with 
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simple fatty liver compared to controls [69]. Recently, in obese pre-pubertal children 
with and without liver steatosis, esRAGE and sRAGE levels were found significantly 
lower in those affected by liver steatosis and were independently related to liver 
steatosis, suggesting that the ligand-RAGE pathway plays an independent role in the 
development of liver injury, already in this age group [70]. 
Cheng et al. [28], using a tissue microarray technique, have studied the expression 
profile of esRAGE in human organs highlighting the distribution of esRAGE as dot-like 
granules in the supranuclear regions facing the luminal surface of the bile ducts; 
esRAGE expression decreased in hepatocytes of patients with obstructive jaundice 
suggesting that esRAGE may contribute to secretion of bile [28]. 
A number of studies have compared different patterns of expression of RAGE, esRAGE 
and ligands in liver specimens among subjects with varying degrees of liver 
impairment. Patients with NASH, but not subjects with simple steatosis, had detectable 
tissue AGEs in hepatocytes [71]. In a study of immunostainings of biopsy specimens 
from subjects of different diagnoses (healthy control, steato-hepatitis, virus related 
hepatitis, cholestasis and cirrhosis), CML and RAGE were detected in hepatocytes of all 
patients, independently of diagnosis [46]. 
Liver tissues from normal, hepatitis and HCC subjects showed co-expression of RAGE 
and HMGB-1 transcripts in all subjects [72]. However, whereas the HMGB-1 
transcripts were comparable with each other, the level of RAGE was different, i.e., 
lower in normal liver compared to hepatitis and highest in HCC [72]. These data 
suggest that RAGE expression is particularly significant in liver of patients with HCC, 
probably because this receptor upregulates the transcription of its own gene through a 
positive feedback loop with its ligands that are produced abundantly during the HCC 
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development (e.g. HMGB-1 may be released from necrotic cells and AGEs generated 
following altered hepatic glycaemic control). 
Over the last decade, data about involvement of the RAGE-ligand axis in inflammation 
and regeneration after solid organ transplantation has emerged from clinical studies on 
the lung [73-75], kidney [73, 74], heart [76], and LT [66, 77, 78]. Interestingly, elevated 
plasma CML levels in patients with liver cirrhosis decreased by 50% three months after 
LT confirming that the liver acts as a clearing organ for AGEs through AGE scavenger 
receptors [66]. 
More importantly, during LT circulating levels of the pro-inflammatory RAGE ligand 
HMGB-1 were undetectable before graft reperfusion and increased after reperfusion, 
and their level was correlated to graft steatosis [77]. These data suggest that HMGB-1 
originates from the graft and may be a marker of hepatocellular injury. 
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AIM OF THE STUDY 
 
During the last few years the scientific interest about the implications of RAGE and its 
ligands in liver impairment has grown up and there are many indications, although not 
unequivocal, about a potential role of RAGE in liver diseases as well as the existence of 
a protective role of sRAGE against the hepatocellular injury. From in vitro and 
experimental studies emerged that the blockade of RAGE attenuated the liver injury 
extent induced by RAGE-ligands. Therefore, the RAGE-ligand axis, through the 
activation of intracellular signals and the resulting production of cytokines, may be 
implicated in the processes of liver inflammation. The primary objective of this study 
was to investigate the association between tissue RAGE isoform (both full-length and 
truncated) mRNA expression with both recipient liver disease and early outcomes after 
liver transplantation. Secondarily, to evaluate trends and changes of circulating RAGE-
ligands and of protective sRAGE in the immediate period following transplantation and 
their association with the development of early organ dysfunction. 
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MATERIAL AND METHODS  
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Material 
Bovine serum albumin (BSA), agarose and RNAlater (Sigma-Aldrich, St Louis, MO), 
96 wells plate (Nunc-Immuno Plates Maxisorp, Denmark), anti-AGE-peroxidase 
conjugated monoclonal antibody (clone 6D12) (Cosmo Bio Co., LTD, Tokyo, Japan), 
ELISA kit for sRAGE (DuoSet ELISA Development kit, R&D systems, Minneapolis, 
MN), tetramethybenzidine (TMB) (Sigma, St. Louis, MO), ELISA kit for HMGB-1 
(double-sandwich ELISA Kit II, IBL International, Hamburg, Germany), RNeasy Midi 
kit, QIAzol lysis reagent and Taq PCR Core Kit (Qiagen S.p.A, Milan, Italy), iScript 
cDNA Synthesis kit (Bio-Rad Laboratories, Inc, Hercules, CA, USA), PCR primers 
(Eurofins MWG Operon), BioPhotometer (Eppendorf Italia, Milan, Italy). Buffers: 
Coating buffer for CML (50 mmol/L baking soda, pH 9.6), coating buffer for sRAGE 
(10 mmol/L PBS, pH 7.2), blocking/reagent buffer (PBS with 1% BSA), washing buffer 
(PBS with 0.05% Tween 20). 
 
Patients enrollment 
We prospectively enrolled twenty eight consecutive patients with end stage liver 
diseases undergoing primarily liver transplantation (LT) at the General Surgery and 
Liver Transplantation Unit of Pisa between November 2010 and April 2012. We 
excluded from the study subjects with at least one of the following conditions: chronic 
kidney disease (serum creatinine values of 1.5 mg/dL or greater), prior heart failure, 
multiple organ graft recipients, inability to provide informed consent to the study. Each 
person provided their medical history, underwent clinical examination, and abdominal 
TAC. MELD score (Mayo End stage Liver Disease) of the patients was calculated 
according with the original version of the MELD scale as developed by investigators at 
Mayo Clinic. All subjects gave written informed consent for their participation in the 
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study which was approved by the IRB (Institutional Review Board) and was conforms 
to the principles outlined in the Declaration of Helsinki. 
 
Liver biopsies and blood samples collection 
Two biopsies were obtained respectively from graft during liver procurement and from 
the explanted liver of the recipients, and were stored at -20°C in RNAlater to stabilize 
the tissues. A single systemic blood sample was drawn from donors and from recipients 
immediately before surgery. During LT, the timing of blood samples collection was 
within 30 minutes after graft reperfusion, 1, 7 and 30 days after LT. Blood samples 
were collected in tubes containing K3EDTA, centrifuged at 4°C and plasma samples 
were immediately stored at -80°C until analysis. All laboratory work was performed in 
blinded fashion with respect to the identity of the samples. Serum alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase 
(GGT), bilirubin, plasma international normalized ratio (INR), Antithrombin III and 
cholinesterase, were determined by standard laboratory methods. 
 
Enzyme-linked immunosorbent-assay (ELISA): determination of sRAGE, CML and 
HMGB-1 plasma levels 
Plasma sRAGE levels were determined using a double-sandwich ELISA kit as 
previously described [79]. Briefly, 96-well microplates were coated with monoclonal 
antihuman RAGE (1 µg/mL) in coating buffer and incubated overnight at room 
temperature (RT). Four rinses with washing buffer followed each incubation step. After 
blocking with reagent buffer at RT for 1 h, 100 µL of sample diluted in reagent diluent 
was added and incubated at RT for 2 h. Recombinant human RAGE was used as 
standard in a concentration range of 31.2–4000 pg/ml. Then 100 µL of biotinylated goat 
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antihuman RAGE (200 ng/ml) was added and incubated at RT for 2 h. Next, 100 µL of 
streptavidin-horseradish peroxidase (1:200) was added and incubated for 20 min at RT. 
Finally, 100 µL of tetramethybenzidine (TMB) substrate was added. After 5–30 min, 50 
µL of 2 mol/L sulfuric acid was added to stop the reaction and OD at 450 nm 
determined by an ELISA plate reader. The intra-assay and inter-assay coefficients of 
variation were less than 5.9% and less than 8.2%, respectively. The lower limit of 
detection of sRAGE was 21.5 pg/ml. 
Plasma CML levels were measured by an in-house competitive ELISA using the 
mouse F(ab’)2 fragment anti-AGE monoclonal antibody as previously described [30]. 
Briefly, CML–BSA in coating buffer was coated for 48h at 4°C on 96-well ELISA 
plates. Wells were washed three times with washing buffer, and then blocked with 
100µl blocking buffer (PBS containing 1% BSA) at room temperature for 1h. After 
three rinses with washing buffer, 50µL of diluted sample were added, followed by 50µl 
of anti-AGE antibody-peroxidase conjugate (0.1µg/mL) in blocking buffer. Chemically 
synthesized CML–BSA was used as standard in a concentration range of 0.1–
100µg/mL. Plates were incubated at room temperature for 3h with gentle agitation on a 
horizontal rotary shaker. After three rinses, 100µl of TMB was then added to each well. 
After 5 to 30min, 50µL of 2 mol/L sulphuric acid was added to stop the reaction and the 
optical density at 450nm determined by an ELISA plate reader. Intra- and inter-assay 
coefficients of variation of our assay were 3.2 and 8.7%, respectively. The lower limit 
of detection of CML was 0.5µg/ml. 
Plasma HMGB-1 levels were determined using the double-sandwich ELISA Kit 
II according to the manufacturers' description. Briefly, 50 µL/well of diluent buffer and 
50 µL of plasma samples, standard or positive control were added at a 96-well 
microplates, precoated with polyclonal antibody specific for HMGB-1, and incubated 
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for 20-24 h at 37°C. Recombinant human HMGB-1 was used as standard in a 
concentration range of 40-1.25 ng/ml. Five rinses with washing buffer followed each 
incubation step. After, 100 µL of POD-conjugate anti-HMGB-1,2 monoclonal antibody 
were added and incubated for 2 h at 25°C. Then, 100 µL of colour solution were added 
to the wells and incubated for 30 min. Thereafter, 100 µL of stop solution were added 
and OD at 450 nm was determined by an ELISA plate reader. Intra-assay and inter-
assay coefficients of variation values were <10%. The sensitivity of the assay was 0.2 
ng/mL. 
 
Total RNA extraction 
Total RNA was extracted from liver specimens as previously described [80] but using 
the RNeasy Midi kit in order to obtain a larger amount of purified RNA. Briefly, tissue 
samples were cut on a sterile plate, weighed and break into pieces. One mL of QIAzol 
lysis reagent was added for each 100 mg of tissue. A stainless steel bead was added to 
the tube and the tissues were homogenized for 5 min at 30 Hz by TissueLyser. The 
homogenate was centrifuged at 10000 g for 10 min at 4°C to remove the insoluble 
material, and the supernatant was transferred in a new tube in which 1 volume of 70% 
ethanol was added. The tube was mixed, then the sample was applied to an Rneasy Midi 
column and processed according to the manufacturers' description. The RNA 
concentration was determined spectrophotometrically at 260 nm. The integrity and 
purity of total RNA were also detected by electrophoresis of samples on ethidium 
bromide 2% agarose gel and visualized at 302 nm (2UVTM Transilluminator, UVP, 
Upland, CA). The RNA samples were stored at -80°C and used for gene expression 
studies. 
 
 
31
Semiquantitative detection of mRNA by RT-PCR  
The reverse transcription of total RNA to cDNA was carried out using iScript cDNA 
Synthesis kit and for template amplification, the Taq PCR Core Kit was used in a 
GeneAmp PCR System 9700 thermalcycler (Pelkin Elmer, Lockport Place, Lorton) 
according to the manufacturers' description. 
The PCR conditions used for human RAGE (isoform_1) (GenBank ID: NM_001136.4) 
were the follow: denaturation at 94°C for 4 min followed by 40 cycles, in which each 
cycle consisted of denaturation at 94°C for 40 sec, annealing at 62°C for 30 sec, 
elongation at 72°C for 50 sec, and final extension at 72°C for 7 min. The primers used 
for RAGE (201 base pair) were: forward 5’-CAG GAA TGG AAA GGA GAC CA-3’ 
and reverse 5’-CCC TTC TCA TTA GGC ACC AG-3’ [81]. The PCR conditions used 
for esRAGE (isoform_6 and 9) (NM_001206940.1 and NM_001206966 respectively) 
were the follow: 95°C for 90 sec followed by 40 cycles of 95°C for 5 sec, 55°C for 15 
sec and 70°C for 25 sec. The primer used for esRAGE (89 bp) were: forward 5’-GGG 
GAT GGT CAA CAA GAA AGG-3’ and reverse 5’-AGG TTC CTC CGA CTG ATT 
CAG TTC-3’. The RAGE and esRAGE mRNA expression were normalized with 
respect to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a constitutive human 
gene used as an internal control. The primers and the PCR reaction steps used for 
GAPDH (354 bp) were: forward 5′-GGT CTC CTC TGA CTT CAA CAG CG-3′ and 
reverse 5′-GGT ACT TTA TTG ATG GTA CAT GAC-3′. The PCR condition used for 
GAPDH were the follows: 95°C for 5 min followed by 30 cycles of 94°C for 1 min, 
55°C for 1 min, 72°C for 1 min, and final extension at 68°C for 7 min [82]. All primers 
were analyzed using Primer BLAST against GenBank database to determine the identity 
of the sequences and the length of the relative PCR products. The amplified products 
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were electrophoresed on ethidium bromide 2% agarose gel, in parallel with a DNA 
Ladder 100 bp and visualized with an ultraviolet transilluminator. 
 
Statistical analysis 
Sample size was calculated with the Stata software (version 9.2; Stata Corp. College 
Station, Texas, USA) by the estimated power for two-sample comparison of means of 
graft esRAGE mRNA values. A sample size of 56 patients (28 per arm) would provide 
85% power to detect differences of 30% in esRAGE value between two groups in a 
two-sided test at an α level of 0.05. Data were analyzed with the use of statistical 
software SPSS 13.0 (SPSS Inc, Chicago, Ill, USA). 
The Kolmogorov–Smirnov test of normality was used to verify whether the distribution 
of variables followed a Gaussian pattern. Data with a normal distribution are given as 
mean±SD. Variables with a skewed distribution are expressed as median and 
interquartile range. Group differences were analyzed by Student t-test, and χ2 test for 
normally distributed, and non-continuous variables, respectively. Variables with a non-
normal distribution were logarithmically transformed before each analysis.  
Multiple differences were evaluated by one way ANOVA followed by Bonferroni post 
hoc test. A multivariate regression analysis, adjusted for donor age, recipient age and 
gender, was used to identify the significant factors associated with the MELD score at 7 
days after-LT. A two-tailed p-value < 0.05 was considered statistically significant. 
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The biochemical and demographic characteristics of donors and recipients (n= 28) 
before surgery and in the first 7 days after surgery are given in Table 1. 
 
Table 1. Donors and recipients characteristics 
Variables   
Donors   
Age (years) 62.1 ± 17.3  
Recipients   
Male (%) 23 (82%)  
Age (years) 53 ± 8.7  
Primary diagnosis, n (%)   
Hepatocellular Carcinoma (HCC)  7 (25%)  
HCC +HCV+ cirrhosis 7(25%)  
HCC +HBV+ cirrhosis 2(7.1%)  
HCV+ cirrhosis 5(17.9%)  
HCC + HBV 1 (3.6%)  
HCC + HCV 1 (3.6%)  
Caroli’s syndrome 2(7.1%)  
Primary sclerosing cholangitis 2(7.1%)  
Alcoholic cirrhosis 1 (3.6%)  
 Before LT On day 7 
Alanine Aminotransferase (ALT) (U/L) 69 (42-90.5) 89 (76.2-119.8) 
Aspartate Aminotransferase (AST) (U/L) 72.5 (59-134.5) 40 (31.2-56.8) 
Gamma-glutamyl transpeptidase (GGT) (U/L) 141.5 (104-197.5) 159 (106-220) 
Lactate Dehydrogenase (LDH) (U/L)  232.7 ± 59.1 234.8 ± 39.4 
Bilirubin (mg/dL) 1.51 (1.1-2.5) 3.28 (1.8-4.4) 
MELD score 9.0 (6.0-13) 9.97(7.7-13.4) 
Cholinesterase (U/L) 2663 (2049-5335)  
Antithrombin III (%)  50 (38-73)  
   
Ascites, n (%) 10 (36%)  
Graft cold ischemia time (minutes) 451.4 ± 91  
Graft warm ischemia time (minutes) 87 ± 15  
Data are presented as mean ±SD, medians and interquartile ranges or percentage. 
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As can be inferred from the table, most of our patients had HCC (64%), were male 
(82%) and with an average age lower than donors (53 ± 8.7 versus 62.1 ± 17.3 
years). 
In Fig. 1 we showed an example of gel electrophoresis for PCR products of RAGE 
(201 bp) in donors and recipients. 
 
 
 
Fig. 1. An example of gel electrophoresis of PCR products of RAGE in donors 
and recipients 
 
From RT-PCR analysis of hepatic full-length RAGE expression emerged that LT 
recipients had higher transcriptional levels of tissueRAGE than donors (972 ± 148 
versus 831 ± 191 mU, p< 0.01). 
The linear regression analysis highlighted that recipient hepatic RAGE mRNA 
expression inversely and significantly correlated with antithrombin III (β= -0.58, p 
= 0.013) (Fig.2A) and with cholinesterase plasma levels (β= -0.717, p= 
0.0018)(Fig.2B), and directly correlate with the pre-operative MELD score (β= 
0.425, p= 0.043)(Fig. 2C). Also HMGB-1 baseline plasma levels directly 
correlated with pre-operative MELD score (β= 0.448, p< 0.05) (Fig. 2D). 
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Fig. 2. Hepatic RAGE mRNA expression inversely correlated with antithrombin III (A) 
and cholinesterase plasma levels (B). The preoperative MELD score directly 
correlated with hepatic RAGE mRNA expression (C) and baseline HMGB-1 
plasma levels (D). 
 
The pre-operative CML plasma levels were higher in LT recipients than donors 
(p=0.02) (Fig 3A). After graft reperfusion they significantly decreased (p<0.0001) and 
quickly returned to basal values one day after LT (Fig. 3A). 
Baseline HMGB-1 levels did not differ between recipients and donors; however the 
values in LT recipients were significantly higher than healthy subjects (3.8 ± 2.3 ng/mL 
versus 0.45 ± 0.3 ng/mL, p<0.0001). The levels of HMGB-1 increased after graft 
reperfusion (39.9 ±18 ng/mL, p<0.0001) and returned readily to baseline values one day 
after LT (3.6 ± 2.9 ng/mL) (Fig 3B). 
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Pre-operative plasma levels of sRAGE did not differ between recipients and donors (Fig 
3C). Plasma sRAGE levels did not change soon after LT but decreased dramatically on 
day 7 (p< 0.0001) (Fig 3C). 
 
 
Fig. 3 Comparison between donors and recipients prior to LT in plasma levels of 
sRAGE (A), CML (B) and HMGB1(C) and kinetics of the same parameters in LT 
recipients at follow-up. 
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Using univariate linear regression analysis, the MELD score on day 7 correlated 
inversely with graft esRAGE mRNA expression (β = -0.48, p = 0.03) (Table 2). 
Instead, the MELD score on day 7 tended to correlate directly with the peak values of 
HMGB-1 after reperfusion (β = 0.42, p = 0.07), with recipient age (β = 0.38, p = 0.07) 
and recipient gender (β = 0.49, p = 0.015) (Table 2). After adjustment for gender, donor 
age, recipient age, multivariate linear regression analysis showed that only graft 
esRAGE mRNA expression remained significantly associated with MELD score on day 
7 (β = -0.788, p = 0.0005) (Table 2). 
 
Table 2. Simple and multiple regression analysis with MELD score on day 
7 as dependent variable 
 β p value
Simple regression analysis 
Age of recipients  0.38 0.07 
Age of donors 0.22 0.3 
Male of recipients 0.49 0.015 
Graft esRAGE mRNA expression -0.48 0.03 
HMGB-1 after reperfusion 0.42 0.07 
Multiple regression analysis
Graft esRAGE mRNA expression -0.788 0.0005
HMGB-1 after reperfusion 0.461 0.013 
Age of recipients  0.494 0.02 
Male of recipients 0.492 0.02 
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DISCUSSION 
 
The present study provides the evidence for the involvement of RAGE and RAGE-
ligands in liver transplantation and graft dysfunction. RAGE tissue levels were 
higher in LT recipients than donors. In a recent study highest level of hepatic RAGE 
expression have been found in patients with HCC [72] and since our population was 
composed mainly by patients with HCC (64%), highest levels of tissue RAGE in 
recipients could be due to most HCC presence [72]. In our patients, the RAGE tissue 
levels inversely correlated with antithrombin III and cholinesterase, two plasmatic 
markers of liver dysfunction that are decreased in patients with liver impairment and 
whose decrease reflects disease severity [83, 84]. This correlation indicates that high 
levels of tissue RAGE can be deleterious for liver survival. This concept is 
confirmed by another significant result, i.e. the direct correlation between the MELD 
score prior to LT, a robust marker of disease severity and mortality, and the tissue 
RAGE. 
Among ligands of RAGE, the most important for the liver impairment is the HMGB-1, 
a protein present in the nucleus of almost all eukaryotic cells which can be released by 
cells undergoing necrosis or in response to hypoxia [49, 59]. It has been demonstrated 
that, during human liver transplantation, circulating levels of HMGB-1 were 
undetectable before graft reperfusion, increased after reperfusion, and correlated with 
graft steatosis [77]. In our study, we confirm the changes of HMGB-1 plasma levels 
during peri-operative period, suggesting that HMGB-1 was released by the transplanted 
liver, maybe following to ischemia/reperfusion (I/R) injury of the organ. The higher 
values of HMGB-1 in LT recipient than in normal subjects and the positive relationship 
between HMGB-1 baseline and pre-operative MELD score, underline the importance of 
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this marker also in chronic liver disease condition [85], so that HMGB-1 could become  
a prognostic marker of liver dysfunction. 
The CML plasma levels were higher in LT recipients than in donors, maybe due to 
patient liver impairment that leads to a reduction in its physiological function of AGEs 
clearance. Further, in LT recipients after an immediate significant reduction, plasma 
CML levels returned to baseline values on day 7 by surgery, underlining the inability of 
the transplanted liver to restart its detoxification function. 
There were no significant differences between LT recipients and donors in sRAGE 
plasma levels. However circulating sRAGE did not change significantly soon after LT 
while decreased dramatically on day 7 after LT (p = 0.0001) and remained constantly 
low during follow-up. We do not know the raison of these changes but can assume that 
they can be due or by an enhanced clearance or by a decreased expression/release, 
possibly affected by immuno-suppression therapy. Since serum creatinine before and 7 
days post-LT does not change, the second hypothesis is more probable and needs to be 
further investigated. On the other hand, in a circumstance very similar to ours such as 
kidney transplant, this protective factor was heavily declined and was associated with 2-
3 times higher risk for mortality in renal transplant recipients [86]. 
The most interesting finding, in our opinion, is the inverse association between the 
expression of esRAGE in donor biopsies with the MELD score on day 7after surgery. 
Although this relationship does not imply causality, it suggests a possible influence of 
esRAGE graft expression on graft dysfunction and survival monitored by the post-
operative MELD score. Therefore, considering these results as a whole, i.e., the 
association between graft esRAGE and MELD score on day 7, the rapid increase of 
HMGB-1 at reperfusion and the CML accumulation in the bloodstream followed by a 
dramatic decline of the protective sRAGE in early post-operative period, we believe that 
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this may result in deleterious consequences on graft survival and outcomes of patients. 
It is so conceivable assume that circulating sRAGE and ligands, tissue esRAGE/RAGE 
expression could be combined with each other in an risk scoring algorithm for graft 
dysfunction prediction after liver transplantation. 
Then RAGE-ligand axis represent a promising target for further investigation as a 
useful biological marker of liver injury prior to LT and perhaps, in patients with early 
allograft dysfunction after LT. Identification of patients at risk of a complicated course 
after LT is crucial for adapting post-operative care. The RAGE–ligand pathway may be 
a worthwhile therapeutic target with a wider therapeutic window aimed at ameliorating 
graft function and survival. 
Our study has several inherent limitations. Clearly, this work is exploratory in nature 
and a descriptive study, therefore cannot assign causality or mechanism to our findings, 
nor can we recommend specific clinical interventions or action based on our 
conclusions. The sample size is the major limiting factor, and a prospective validation 
set is still needed for more definitive conclusions and to confirm any clinical 
associations. We also recognize some limitations in missed early clinical time points in 
the first week after LT. 
Despite these limitations, this study provides evidence for several associations 
between specific inflammatory mediators, linked to RAGE,  and graft dysfunction 
that can guide future investigation.  
In conclusion, the plasma levels of sRAGE, HMGB-1 and CML and the tissue levels of 
RAGE and esRAGE in recipient and in liver graft, may be promising targets for further 
investigation as mediators of liver injury post-transplantation, and serve as potential 
clinical biomarkers for prediction of early detection of graft dysfunction and the 
possibility of graft loss. 
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